Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05067790 · ClinicalTrials.gov registry record · Phase 3
A Study to Learn About the Effect of Higher Doses of Nusinersen (BIIB058) Given as Injections to Participants With Spinal Muscular Atrophy (SMA) Who Were Previously Treated With Risdiplam (ASCEND)
A Phase 3 study of Spinal Muscular Atrophy, sponsored by Biogen.
- Active
- Registry status
- Phase 3
- Development phase
- 45
- Enrollment target
- 20
- Study locations
NCT05067790 is a Phase 3 study of Spinal Muscular Atrophy that is active but no longer recruiting, run by Biogen. The registered enrollment target is 45 participants, below the 107-participant average among 22 other Spinal Muscular Atrophy trials with a reported enrollment target (58% lower). The trial reports 20 study locations across 18 states.
The verdict
NCT05067790, a Phase 3 study of Spinal Muscular Atrophy, is active but no longer recruiting, sponsored by Biogen.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 45 participants
- Enrollment target
- 20
- Study locations
Study Summary
In this study, researchers will learn more about the use of a higher dose of nusinersen (BIIB058) in participants with spinal muscular atrophy (SMA). This study will focus on teenagers and adults who are unable to walk on their own and who have previously taken another drug for SMA called risdiplam. The main goal of this study is to learn about the effect of high dose (HD) nusinersen on muscle and movement ability (motor function) in SMA. The main question that researchers want to answer is: \- How do the scores of a movement test called the Revised Upper Limb Module change from the start of treatment? The Revised Upper Limb Module is a test used to measure a participant's ability to do specific tasks that involve their shoulders, arms, wrist, elbows, and hands. It measures the changes in their abilities over time. Researchers will also learn more about the safety of HD nusinersen. They will check participants for adverse events and changes in vital signs, heart tests, and laboratory tests including blood and urine tests. The study will be done as follows: * Participants will be screened to check if they can join the study. * After screening, participants will enter the Core Treatment period. * At the start of the Core Treatment period, they will receive 2 "loading" doses of nusinersen. These are 50 mg doses of nusinersen given 2 weeks apart. * Afterwards, they will continue to receive "maintenance" doses of nusinersen once every 4 months. These doses will be 28 mg. * The Core Treatment period will last about 2 years, with a follow-up visit 4 months after the last dose. * Participants who complete the Core Treatment period will have the option to continue receiving 28 mg of nusinersen in the Long-Term Extension (LTE) period for about 2 years. There will also be a follow-up visit 4 months after the last dose. * Nusinersen will be given through a lumbar puncture, which involves injecting the drug into the fluid around the spinal cord in the lower back. * In tota
Conditions Studied
Interventions
- DRUG Nusinersen
Study Locations (20)
California
- Loma Linda University Children's Hospital - Loma Linda
- Stanford Neuroscience Health Center - Palo Alto
Texas
- Neurology Rare Disease Center - Denton
- The University of Texas Health Science Center at Houston - Houston
Arizona
- Barrow Neurological Institute - Phoenix
Arkansas
- Arkansas Children's Hospital - Little Rock
District of Columbia
- Georgetown University - Washington D.C.
Georgia
- Rare Disease Research, LLC - Atlanta
Illinois
- Ann & Robert H. Lurie Children's Hospital of Chicago - Chicago
Iowa
- University of Iowa Stead Family Children's Hospital - Iowa City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2022-01-21 |
| Est. Completion | 2027-06-14 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05067790
The ClinicalTrials.gov registry entry for NCT05067790 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 45 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 107-participant average among 22 other Spinal Muscular Atrophy trials with a reported enrollment target (58% lower). The listed sponsor is Biogen, which has 334 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Spinal Muscular Atrophy appearing as the primary indexed condition, and to 1 intervention - of which Nusinersen is the first listed.
NCT05067790 reports 20 study locations spanning 18 distinct geographic areas - top geographies include California, Texas, Arizona.
Frequently Asked Questions
What is clinical trial NCT05067790 about?
NCT05067790 is a clinical study titled "A Study to Learn About the Effect of Higher Doses of Nusinersen (BIIB058) Given as Injections to Participants With Spinal Muscular Atrophy (SMA) Who Were Previously Treated With Risdiplam (ASCEND)". In this study, researchers will learn more about the use of a higher dose of nusinersen (BIIB058) in participants with spinal muscular atrophy (SMA). This study will focus on teenagers and adults who are unable to walk on their own and who have previously taken another drug for SMA called risdiplam....
What is the current status of trial NCT05067790?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 45 participants. The study started on 2022-01-21. Estimated completion is 2027-06-14.
What conditions does trial NCT05067790 study?
This clinical trial studies the following conditions: Spinal Muscular Atrophy.
What interventions are being tested in trial NCT05067790?
The interventions under investigation include: Nusinersen (DRUG).
Who is sponsoring clinical trial NCT05067790?
This trial is sponsored by Biogen, which has 334 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05067790 being conducted?
This trial has 20 study locations across Arizona, Arkansas, California, District of Columbia, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Spinal Muscular Atrophy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate the Efficacy and Safety of Taldefgrobep Alfa in Participants With Spinal Muscular Atrophy
ACTIVE NOT RECRUITING · Phase 3
-
Long-Term Safety & Efficacy of Apitegromab in Patients With SMA Who Completed Previous Trials of Apitegromab
ACTIVE NOT RECRUITING · Phase 3
-
Efficacy and Safety of Apitegromab in Patients With Later-Onset Spinal Muscular Atrophy Treated With Nusinersen or Risdiplam
COMPLETED · Phase 3
-
Characterizing Perceived Physical Fatigability in Nusinersen-treated SMA
RECRUITING
-
Effects of Whole-body Electrical Muscle Stimulation Exercise on Adults With Neuromuscular Disease
RECRUITING · NA
-
Safety and Efficacy of NMD670 in Ambulatory Adult Patients With Type 3 Spinal Muscular Atrophy
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.